Oxford Cannabinoid Technologies Holdings plc

Company Profile

Company website
Pharmaceuticals and Biotechnology (Biotechnology)

Established in 2017, OCT aims to become a global leader in developing licensed prescription medicines that target the endocannabinoid system to address significant unmet medical needs.

To achieve its aim, OCT uses a drug development strategy that includes proprietary cannabinoid derivatives, natural phytocannabinoids (pCBs), and in-licensed compounds. Our primary market focus is the pain market, and OCT initially aims to develop a portfolio of four drug candidates for approval as licensed pain medicines.

Since inception, the company has grown significantly, expanded its research and library of cannabinoid derivatives, and completed four rounds of investment.

Investor Access

28 Sep
Event information

Management will hold the company’s AGM meeting at 11:30 on 28th September 2022 relating to the accounts for the 11 month period to 30th April 2022.

Penningtons Manches Cooper LLP, 125 Wood Street, London EC2V 7AW

Wednesday 28th September 2022 at 11:30

Financial Calendar
Event Date
Year End31 May
Half  Year End30 November
Preliminary Results*October
Interim Results*January

* Months based on previous announcements of this kind